You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Magnetic Flow Sorter for Pancreatic Islet Isolation

    SBC: TECHSHOT, INC.            Topic: 200

    DESCRIPTION provided by applicant Techshot Inc has successfully completed SBIR Phase I and Phase II research demonstrating that magnetically labeled porcine islets of Langerhans can be isolated from contaminating exocrine tissue by flow sorting using a quadrupole magnetic separator andquot Quadrasepandquot designed for that purpose Magnetically sorted islets are superior in morphology and ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Novel anti-viral agents to treat influenza

    SBC: ALEXANDER BIODISCOVERIES, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Yearly influenza epidemics affect about of the worldandapos s population and estimates of annual mortality range from including approximately deaths and hospitalizations in the United States In addition the likelihood of a severe pandemic caused by a newly emergent strain of influenza virus is very high given that three such pandemics were recorded in the th centu ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Distributed REMD Simulation for Probing Alzheimer Molecular Mechanisms

    SBC: PARABON COMPUTATION, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of

    SBC: AARDEN PHARMACEUTICALS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of tuberculosis Aarden Pharmaceuticals Project Summary/Abstract The need exists for a new, breakthrough therapeutic for tuberculosis (TB). Current treatment regimens with toxic chemotherapeutic drugs are too long, causing poor compliance which results in reduced efficacy and the emer ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Temperature-Tolerant COLD-PCR enables mutation-enriched targeted re-sequencing

    SBC: TRANSGENOMIC, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Cancers develop from the life-long accumulation of critical somatic mutations due to DNA-damaging agents that lead to cells transforming into tumor-forming cells. These low-level tumor-associated somatic DNA mutations can have profound implications for development of metastasis, prognosis, choice of treatment, follow-up or early cancer detection. Unless they ar ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Novel LANCL2-based Anti-diabetic Compounds

    SBC: Biotherapeutics, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): About 28.3 million Americans have type II diabetes (T2D) and over 40.1% of middle-aged adults have prediabetes, a condition characterized by impaired glucose tolerance and insulin resistance. Current antidiabetic medications are effective in improving insulin sensitivity, but their chronic administration has significant side effects suc as cardiovascular compli ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government